North America Drug Delivery Devices Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2024 –2031 |
 Tamanho do mercado (ano base ) | USD 788.49 Billion |
 Tamanho do mercado ( Ano de previsão) | USD 1,351.11 Billion |
 CAGR |
% |
| Principais participantes do mercado |
|
>Mercado de dispositivos de administração de medicamentos da América do Norte, por tipo de produto ( entrega de medicamentos oraisentrega de medicamentos injetáveis, entrega de medicamentos tópicos, entrega de medicamentos oftálmicos, entrega de medicamentos nasaisentrega de medicamentos pulmonares , entrega de medicamentos transmucosais e entrega de medicamentos implantáveis ), utilizador final (hospitais, Cuidados de Saúde Domiciliários, Clínicas, Cuidados de Saúde Comunitários e Outros), Canal de Distribuição (Concursos Directos, Farmácias Hospitalares, Farmácias e Farmácias Online) - Tendências e Previsões do Sector para 2031.
Análise e dimensão do mercado de dispositivos de administração de medicamentos na América do Norte
O mercado norte-americano de dispositivos de administração de medicamentos está a registar um crescimento significativo, impulsionado pela crescente prevalência de doenças crónicas e não crónicas, pelo crescimento no desenvolvimento de dispositivos de medicamentos biológicos e pela crescente consciencialização sobre o diagnóstico e o tratamento. O mercado é caracterizado pela presença de um grande número de players que oferecem uma vasta gama de dispositivos de diagnóstico adaptados para satisfazer as diversas necessidades dos prestadores de cuidados de saúde da região.
A Data Bridge Market Research analisa que o mercado norte-americano de dispositivos de administração de medicamentos está a crescer com um CAGR de 7,3% no período previsto de 2024 a 2031 e deverá atingir os 1.351,11 mil milhões de dólares até 2031, de US$ 788,49 mil milhões de dólares em 2023.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2024 a 2031 |
|
Ano base |
2023 |
|
Ano histórico |
2022 (personalizável 2016-2021) |
|
Unidades Quantitativas |
Receita em biliões de dólares |
|
Segmentos cobertos |
Tipo de produto (administração de medicamentos orais, administração de medicamentos injetáveis, administração de medicamentos tópicos, administração de medicamentos oftálmicos, administração de medicamentos nasais, administração de medicamentos pulmonares , administração de medicamentos transmucosais e administração de medicamentos implantáveis), utilizador final (hospitais, cuidados de saúde domiciliários, clínicas, cuidados de saúde comunitários e Outros), Canal de Distribuição (Concursos Directos, Farmácias Hospitalares, Farmácias Lojas e Farmácia Online) |
|
Países abrangidos |
EUA, Canadá e México |
|
Participantes do mercado abrangidos |
BD, F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, Johnson & Johnson Services, Inc., 3M, Gerresheimer AG, Medmix, OraSure Technologies Inc., Enable Injection, Insulet Corporation, Bayer AG, Pfizer Inc., GSK plc ., Merck & Co., Inc., Amgen Inc., AbbVie Inc., Elcam Medical, SMC Ltd., ViVO Smart Medical Devices Ltd., West and Pharmaceutical Services, Inc. |
Definição de mercado
Drug delivery devices are medical devices designed to deliver medications to the body in a controlled and targeted manner, enhancing their efficacy, safety, and patient compliance. These devices can be external, such as inhalers, injectors, and pumps, or internal such as implantable devices, and are used to administer a wide range of medications, including small molecules, biologics, and vaccines. They can modify the release rate, bioavailability, and absorption of drugs, as well as provide real-time monitoring and feedback to patients and healthcare providers. Drug delivery devices play a crucial role in optimizing treatment outcomes and improving patient quality of life for various diseases and conditions, including chronic conditions, infectious diseases, and cancer.
North America Drug Delivery Devices Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Rising Prevalence of Chronic Disease and Non-Chronic Disease
The prevalence of diseases and conditions such as Cardiovascular Diseases (CVDs), asthma, cancer, neurological disorders, stroke, diabetes, and respiratory diseases has increased significantly over some time. Mentioned below are some of the important statistics related to some of the chronic diseases. The rising prevalence of chronic and non-chronic diseases significantly influences the growth of the drug delivery devices market. Chronic diseases such as diabetes, cardiovascular diseases, and respiratory disorders are becoming more widespread, necessitating long-term treatment plans that require efficient and reliable drug delivery device methods.
- Growth in the Development of Biologics Drugs Devices
Biologics is considered one of the fastest-growing segments in the pharmaceutical market. Development and manufacturing of biologics for both branded and generic drugs is becoming increasingly competitive with the presence of players. Biologics are generally administered through injections in the arms, legs or abdomen. For instance, Cimzia, Cosentyx, Enbrel, and Humira among others.
Opportunity
- Rising Acceptance of Self-Administering Drug Devices
Self-administration of drugs by the patients is expected to provide significant growth opportunities for drug delivery players focusing on the development of innovative and new devices. Major factors contributing to this are growing elderly population, as aged population forms large consumer base for homecare drug delivery devices. Pharmaceutical companies are focusing on the development of patient-friendly therapies and self-administered drug-device combination products. With the increasing acceptance of self-administration, the need for application-specific injection, inhalation, topical, and transdermal drug products is also increasing.
Restraint/Challenge
- Side Effects of Drug Delivery Systems
Adverse reactions to drug delivery systems can lead to a decrease in patient compliance, which can result in decreased demand for the device. This can negatively impact the sales and revenue of the device manufacturer. Side effects can raise concerns about patient safety, leading to increased scrutiny and regulation from regulatory agencies. This can lead to delays in product launches, additional testing requirements, and increased costs for device manufacturers. Moreover, side effects can lead to device rejection by patients, resulting in a decrease in demand for the device. This can be particularly problematic for devices that require long-term use, such as implantable devices.
Recent Developments
- In August 2023, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. submitted the supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking sanction of DARZALEX in combination with Kyprolis and dexamethasone for relapsed/refractory multiple myeloma. If approved this will increase the product portfolio and also revenue generation of the company
- In January 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. announced that EC has given the grant to market Erleada which is used to treat metastatic hormone-sensitive prostate cancer (mHSPC) in combination with Androgen Deprivation Therapy (ADT). This will increase their market presence which will further increase the revenue generation
- In December 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. announced the EC approval of SPRAVATO nasal spray, which will enhance their product portfolio which will further increase the revenue
North America Drug Delivery Devices Market Scope
The North America drug delivery devices market is segmented into three notable segments based on product type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Product Type
- Oral Drug Delivery
- Injectable Drug Delivery
- Topical Drug Delivery
- Ophthalmic Drug Delivery
- Nasal Drug Delivery
- Pulmonary Drug Delivery
- Transmucosal Drug Delivery
- Implantable Drug Delivery
On the basis of product type, the North America drug delivery devices market is segmented into injectable drug delivery formulations, injectable drug delivery, topical drug delivery, ophthalmic drug delivery, nasal drug delivery, pulmonary drug delivery, transmucosal drug delivery, and implantable drug delivery.
End User
- Hospitals
- Home Healthcare
- Clinics
- Community Healthcare
- Others
On the basis of end user, the North America drug delivery devices market is segmented into hospitals, home healthcare, clinics, community healthcare and others.
Distribution Channel
- Direct Tenders
- Hospital Pharmacies
- Pharmacy Stores
- Online Pharmacy
Com base no canal de distribuição, o mercado norte-americano de dispositivos de administração de medicamentos está segmentado em concursos diretos, farmácias hospitalares, farmácias e farmácias online.
Análise/perspetivas regionais do mercado de dispositivos de administração de medicamentos da América do Norte
O mercado norte-americano de dispositivos de administração de medicamentos é analisado, e os insights e tendências do tamanho do mercado são fornecidos com base no tipo de produto, utilizador final e canal de distribuição, conforme mencionado acima.
Os países abordados neste relatório de mercado são os EUA, o Canadá e o México.
Prevê-se que a América do Norte domine o mercado devido a factores como a sua infra-estrutura de cuidados de saúde avançada, o elevado investimento em I&D e a forte procura de tecnologias médicas inovadoras.
Prevê-se que os EUA dominem o mercado da América do Norte devido à sua infra-estrutura avançada de cuidados de saúde, ao investimento significativo em investigação e desenvolvimento e a um quadro regulamentar robusto que apoia a inovação.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.
Análise do panorama competitivo e da quota de mercado dos dispositivos de administração de medicamentos na América do Norte
O mercado norte-americano de dispositivos de administração de medicamentos está segmentado em três segmentos notáveis com base no tipo de produto, utilizador final e canal de distribuição.
O panorama competitivo do mercado de dispositivos de administração de medicamentos na América do Norte fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, e domínio da aplicação. Os dados fornecidos acima estão apenas relacionados com o foco das empresas no mercado norte-americano de dispositivos de administração de medicamentos.
Alguns dos principais players que operam no mercado norte-americano de dispositivos de administração de medicamentos são a BD, F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, Johnson & Johnson Services, Inc., 3M, Gerresheimer AG, Medmix, OraSure Technologies Inc. , Enable Injection, Insulet Corporation, Bayer AG, Pfizer Inc., GSK plc., Merck & Co., Inc., Amgen Inc., AbbVie Inc., Elcam Medical, SMC Ltd., ViVO Smart Medical Devices Ltd. , West e Pharmaceutical Services, Inc., entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE
6.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS DRUGS DEVICES
6.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT
6.1.4 INCREASED FOCUS ON PERSONALIZED MEDICINE AND DEVICES
6.2 RESTRAINTS
6.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
6.2.2 HIGH COSTS OF INJECTABLE DRUGS
6.2.3 STRINGENT REGULATORY SCENARIO
6.3 OPPORTUNITIES
6.3.1 RISING ACCEPTANCE OF SELF-ADMINISTERING DRUG DEVICES
6.3.2 RISING DEMAND FOR BIOSIMILAR AND GENERIC DRUGS
6.3.3 THERAPEUTIC ADVANCEMENTS IN THE FIELD OF DRUG DELIVERY
6.4 CHALLENGES
6.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS
6.4.2 INCREASE IN THE NUMBER OF ALTERNATIVES OF DRUG DELIVERY
7 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 ORAL DRUG DELIVERY
7.2.1 SOLID ORAL DRUGS
7.2.1.1 TABLETS
7.2.1.2 CAPSULES
7.2.1.3 PILLS
7.2.1.4 POWDERS
7.2.2 LIQUID ORAL DRUGS
7.2.2.1 SYRUPS
7.2.2.2 SOLUTIONS
7.2.3 SEMI SOLID ORAL DRUGS
7.2.3.1 GELS
7.2.3.2 EMULSIONS
7.2.3.3 ELIXIRS
7.3 INJECTABLE DRUG DELIVERY
7.3.1 INJECTABLE DRUG DELIVERY FORMULATIONS
7.3.1.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.3.1.2 NOVEL DRUG DELIVERY FORMULATIONS
7.3.1.3 LONG ACTING INJECTION FORMULATIONS
7.3.2 INJECTABLE DRUG DELIVERY DEVICES
7.3.2.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
7.3.2.1.1 BY MATERIAL
7.3.2.1.1.1 GLASS
7.3.2.1.1.2 PLASTIC
7.3.2.1.2 BY PRODUCT TYPE
7.3.2.1.2.1 FILLABLE
7.3.2.1.2.2 PRE-FILLED
7.3.2.1.3 BY USABILITY
7.3.2.1.3.1 REUSABLE SYRINGES
7.3.2.1.3.2 DISPOSABLE SYRINGES
7.3.2.2 SELF INJECTION DRUG DELIVERY DEVICES
7.3.2.2.1 NEEDLE FREE INJECTORS
7.3.2.2.2 WEARABLE INJECTORS
7.3.2.2.3 PEN INJECTOR
7.3.2.2.4 AUTO INJECTORS
7.3.2.2.5 OTHERS
7.4 TOPICAL DRUG DELIVERY
7.4.1 TRANSDERMAL DRUG DELIVERY FORMULATIONS
7.4.1.1 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.1.1 OINTMENTS
7.4.1.1.2 CREAMS
7.4.1.1.3 LOTIONS
7.4.1.1.4 GELS
7.4.1.1.5 PASTES
7.4.1.2 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.2.1 SUSPENSIONS
7.4.1.2.2 SOLUTIONS
7.4.1.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.3.1 POWDER
7.4.1.3.2 SUPPOSITORS
7.5 OPHTHALMIC DRUG DELIVERY
7.5.1 OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.1 LIQUID OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.1.1 SOLUTIONS
7.5.1.1.2 SUSPENSIONS
7.5.1.2 SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.2.1 GELS
7.5.1.2.2 OINTMENTS
7.5.2 OCCULAR DRUG DELIVERY DEVICES
7.6 NASAL DRUG DELIVERY
7.6.1 NASAL DROPS
7.6.2 NASAL SPRAYS
7.6.3 NASAL POWDERS
7.6.4 NASAL GELS
7.7 PULMONARY DRUG DELIVERY
7.7.1 METERED DOSE INHALERS (MDI)
7.7.2 DRY POWDER INHALERS (DPI)
7.7.3 NEBULIZERS
7.7.3.1 JET NEBULIZERS
7.7.3.2 ULTRASONIC NEBULIZERS
7.7.3.3 SOFT MIST NEBULIZERS
7.8 TRANSMUCOSAL DRUG DELIVERY
7.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY
7.8.1.1 BUCCAL DRUG DELIVERY
7.8.1.2 SUBLINGUAL DRUG DELIVERY
7.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY
7.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY
7.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY
7.9 IMPLANTABLE DRUG DELIVERY
7.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
7.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
8 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 HOME HEALTHCARE
8.4 CLINICS
8.5 COMMUNITY HEALTHCARE
8.6 OTHERS
9 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT TENDERS
9.3 HOSPITAL PHARMACIES
9.4 PHARMACY STORES
9.5 ONLINE PHARMACY
10 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY REGION
10.1 NORTH AMERICA
10.1.1 U.S.
10.1.2 CANADA
10.1.3 MEXICO
11 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 JOHNSON & JOHNSON SERVICES, INC.
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 NOVARTIS AG
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 PRODUCT PORTFOLIO
13.2.5 RECENT DEVELOPMENTS
13.3 F. HOFFMANN-LA ROCHE LTD
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENT
13.4 BAYER AG
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 PRODUCT PORTFOLIO
13.5 PFIZER INC.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 COMPANY SHARE ANALYSIS
13.5.4 PRODUCT PORTFOLIO
13.5.5 RECENT DEVELOPMENT
13.6 3M
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 ABBVIE INC.
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 AMGEN INC.
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENTS
13.9 BD
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENT
13.1 ELCAM MEDICAL
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENT
13.11 ENABLE INJECTIONS
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENTS
13.12 GERRESHEIMER AG
13.12.1 COMPANY SNAPSHOT
13.12.2 REVENUE ANALYSIS
13.12.3 PRODUCT PORTFOLIO
13.12.4 RECENT DEVELOPMENTS
13.13 GSK PLC.
13.13.1 COMPANY SNAPSHOT
13.13.2 REVENUE ANALYSIS
13.13.3 PRODUCT PORTFOLIO
13.13.4 RECENT DEVELOPMENTS
13.14 INSULET CORPORATION
13.14.1 COMPANY SNAPSHOT
13.14.2 REVENUE ANALYSIS
13.14.3 PRODUCT PORTFOLIO
13.14.4 RECENT DEVELOPMENTS
13.15 MEDMIX
13.15.1 COMPANY SNAPSHOT
13.15.2 REVENUE ANALYSIS
13.15.3 PRODUCT PORTFOLIO
13.15.4 RECENT DEVELOPMENTS
13.16 MERCK & CO., INC.
13.16.1 COMPANY SNAPSHOT
13.16.2 REVENUE ANALYSIS
13.16.3 PRODUCT PORTFOLIO
13.16.4 RECENT DEVELOPMENT
13.17 ORASURE TECHNOLOGIES INC.
13.17.1 COMPANY SNAPSHOT
13.17.2 REVENUE ANALYSIS
13.17.3 PRODUCT PORTFOLIO
13.17.4 RECENT DEVELOPMENT
13.18 SANOFI
13.18.1 COMPANY SNAPSHOT
13.18.2 REVENUE ANALYSIS
13.18.3 PRODUCT PORTFOLIO
13.18.4 RECENT DEVELOPMENTS
13.19 SMC LTD.
13.19.1 COMPANY SNAPSHOT
13.19.2 REVENUE ANALYSIS
13.19.3 PRODUCT PORTFOLIO
13.19.4 RECENT DEVELOPMENTS
13.2 VIVO SMART MEDICAL DEVICES LTD.
13.20.1 COMPANY SNAPSHOT
13.20.2 PRODUCT PORTFOLIO
13.20.3 RECENT DEVELOPMENT
13.21 WEST PHARMACEUTICAL SERVICES, INC.
13.21.1 COMPANY SNAPSHOT
13.21.2 REVENUE ANALYSIS
13.21.3 PRODUCT PORTFOLIO
13.21.4 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
Lista de Tabela
TABLE 1 LIST OF FDA APPROVED BIOLOGICS, IN 2022
TABLE 2 10 MOST EXPENSIVE DRUGS IN THE U.S. (IN USD MILLION)
TABLE 3 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 4 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 6 NORTH AMERICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 7 NORTH AMERICA LIQUID ORAL DRUG IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 8 NORTH AMERICA SEMI SOLID ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 9 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 11 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 12 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 13 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 14 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE 2022-2031 (USD MILLION)
TABLE 15 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 16 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 18 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 20 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 25 NORTH AMERICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 26 NORTH AMERICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 27 NORTH AMERICA SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 30 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 32 NORTH AMERICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 36 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 40 NORTH AMERICA HOSPITALS IN DRUG DELIVERY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 41 NORTH AMERICA HOME HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 42 NORTH AMERICA CLINICS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 NORTH AMERICA COMMUNITY HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 NORTH AMERICA OTHERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 46 NORTH AMERICA DIRECT TENDERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 47 NORTH AMERICA HOSPITAL PHARMACIES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 48 NORTH AMERICA PHARMACY STORES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 49 NORTH AMERICA ONLINE PHARMACY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 50 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 51 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 52 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 53 NORTH AMERICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 54 NORTH AMERICA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 55 NORTH AMERICA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 56 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 57 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 58 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 59 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 60 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 61 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 62 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 63 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 64 NORTH AMERICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 65 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 67 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 69 NORTH AMERICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 70 NORTH AMERICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 NORTH AMERICA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 72 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 73 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 74 NORTH AMERICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 75 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 76 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 77 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 78 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 79 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 80 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 81 U.S. DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 82 U.S. ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 83 U.S. SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 84 U.S. LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 85 U.S. SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 86 U.S. INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 87 U.S. INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 88 U.S. INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 89 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 90 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 91 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 92 U.S. SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 93 U.S. TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 94 U.S. TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 95 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 96 U.S. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 U.S. SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 U.S. OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 99 U.S. OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 100 U.S. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 101 U.S. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 102 U.S. NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 103 U.S. PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 104 U.S. NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 105 U.S. TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 106 U.S. ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 107 U.S. OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 108 U.S. IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 109 U.S. DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 110 U.S. DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 111 CANADA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 112 CANADA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 113 CANADA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 114 CANADA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 115 CANADA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 116 CANADA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 117 CANADA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 118 CANADA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 119 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 120 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 121 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 122 CANADA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 123 CANADA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 124 CANADA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 125 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 CANADA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 CANADA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 CANADA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 129 CANADA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 130 CANADA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 CANADA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 CANADA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 133 CANADA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 134 CANADA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 135 CANADA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 136 CANADA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 137 CANADA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 138 CANADA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 139 CANADA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 140 CANADA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 141 MEXICO DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 142 MEXICO ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 143 MEXICO SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 144 MEXICO LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 145 MEXICO SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 146 MEXICO INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 147 MEXICO INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 148 MEXICO INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 149 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 150 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 151 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 152 MEXICO SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 153 MEXICO TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 154 MEXICO TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 155 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 MEXICO LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 157 MEXICO SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 158 MEXICO OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 159 MEXICO OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 160 MEXICO LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 MEXICO SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 MEXICO NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 163 MEXICO PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 164 MEXICO NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 165 MEXICO TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 166 MEXICO ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 167 MEXICO OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 168 MEXICO IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 169 MEXICO DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 170 MEXICO DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
Lista de Figura
FIGURE 1 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 EIGHT SEGMENTS COMPRISE THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE ARE DRIVING THE GROWTH OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET FROM 2024 TO 2031
FIGURE 15 THE ORAL DRUG DELIVERY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET IN 2024 AND 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA DRUG DELIVERY DEVICES MARKET
FIGURE 17 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023
FIGURE 18 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023-2031 (USD MILLION)
FIGURE 19 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 20 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA DRUG DELIVERY MARKET: BY END USER, 2023
FIGURE 22 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 23 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: END USER, CAGR (2024-2031)
FIGURE 24 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: END USER, LIFELINE CURVE
FIGURE 25 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 26 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 27 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 28 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 29 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE 2023 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
